Benzotriazole is a bicyclic nitrogen heterocycle formed by the fusion of the benzene ring with the 4,5-positions or the “d” site of 1H-1,2,3-triazole. The benzotriazoles are known as important intermediates in the preparation of organic products such as β-amido ketones, aldehydes, β-ketoesters, ionic liquid, and as reagents for acylation and thioacylation reactions. 1H-Benzotriazoles are also known to exhibit broad spectrum of pharmacological activities. There are numerous benzotriazole-based clinically used drugs in the market for the treatment of various diseases.
The elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), and heterozygous familial hypercholesterolemia (HeFH). Cholesteryl ester transfer protein (CETP) transports cholesterol from good high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C). NewAmsterdam’s Obicetrapib is a novel, selective CETP inhibitor to address the limitations of current treatments.
Obicetrapib is under investigation in phase III clinical trials as a monotherapy product, and in phase II studies as a fixed dose combination with Ezetimibe.
Buscar 
+86 21 5895 0110 
